Interview with Harpoon's CEO Jerry McMahon

17th December 2019

Stay Updated

Add your email below to stay updated with useful and informative content from Arix and our portfolio companies

Jerry McMahon discusses Harpoon's novel antibody-derived platform which has been designed to use T-cells to target and destroy solid tumors in prostate, ovarian, pancreatic and other solid cancers.